ClinicalTrials.gg
RecruitingNCT05038462Updated Nov 9, 2026

Fetal Brain Care: Therapies for Brain Neurodevelopment in Fetal Growth Restriction

An interventional study of Lactoferrin and DHA and Placebo in Fetal Growth Retardation and Intrauterine Growth Restriction, sponsored by Institut d'Investigacions Biomèdiques August Pi i Sunyer. Recruiting at 6 sites in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Institut d'Investigacions Biomèdiques August Pi i Sunyer · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.
Updated Nov 9, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
304
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies in Fetal Growth Retardation with a site in Spain — 7 open to participants now, 7 under way, none of them phase 3. Fetal Growth Retardation · Spain.

Planned enrollment
7th of 11
304 · median 340
Started
2023
with 2 others
No phase
8 of 18
3 open now
Registered
13th of 18
by date
Lead sponsor
1 of 18
Institut d'Investigacions Biomèdiques August Pi i Sunyer

Among the 18 studies in Fetal Growth Retardation with a site in Spain, this one is the 7th largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2023, is one of 8 with no phase, and was the 13th registered.

Fetal Growth Retardation

262 studies on the registry are indexed under Fetal Growth Retardation; 69 are open to participants now.

Browse Fetal Growth Retardation studies →

Open to participants now

7 of the 18 studies in Fetal Growth Retardation with a site in Spain are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 48 Fetal Growth Retardation studies recruiting now, 24 (50%) set no upper age limit and 21 (44%) stop at 75 or younger; 16 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Fetal Growth Retardation with a site in Spain, or all of them as a file.
02

Study summary

Singleton pregnancies being diagnosed of fetal growth restriction from 24 to 32.6 weeks of gestation will be randomized to two equally sized groups: maternal oral supplementation with Lactoferrin and DHA (Docosahexaenoic acid) or placebo.

Read the detailed description

Randomized controlled trial among pregnant women that have been diagnosed of fetal growth restriction. These women will be randomized in order to evaluate the impact of maternal supplementation with Lactoferrin and DHA on the neurodevelopment outcome of their babies.

Main hypothesis: a prenatal intervention based on maternal supplementation with Lactoferrin and DHA improves neurodevelopment in fetal growth restriction.

Secondary hypothesis are that a prenatal intervention based on maternal supplementation with Lactoferrin and DHA in fetal growth restriction improves fetal growth and improves perinatal morbidity and mortality.

03

Conditions studied

  • Fetal Growth Retardation
  • Intrauterine Growth Restriction

Keywords

  • Fetal Growth Retardation
  • Fetal Growth Restriction
  • Intrauterine Growth Restriction
  • Neurodevelopment
  • Lactoferrin
  • DHA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Singleton pregnancies
  • Non-malformed fetus
  • Pregnancies with fetal growth restriction
  • 24-32.6 weeks of gestation

Exclusion criteria

Exclusion Criteria:

  • Chromosomal or structural abnormalities diagnosed during pregnancy or in the neonatal period
  • Critical Doppler study suggesting the need for delivery within the next 14 days at the time of diagnosis: reverse end-diastolic velocity in the umbilical artery or ductus venosus pulsatility >95th centile
  • Maternal mental or psychiatric disorders
  • Maternal allergy to cow's milk protein
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
304 participants (estimated)

Study arms

  • Active comparator
    Maternal supplementation with Lactoferrin and DHA

    The intervention consists in the maternal oral administration of 1000mg of Lactoferrin and 1000mg of DHA daily

    Dietary Supplement: Lactoferrin and DHA

  • Placebo comparator
    Placebo

    Product with the same physical appearance and taste as the main intervention but without therapeutic effect

    Other: Placebo

Interventions

  • Dietary supplementLactoferrin and DHA

    Drug page: LactoferrinStudies of LactoferrinLactoferrin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The intervention consists in the maternal oral administration of 1000mg of Lactoferrin and 1000mg of DHA daily

  • OtherPlacebo

    Product with the same physical appearance and taste as the main intervention but without therapeutic effect

06

What researchers measure

Primary outcomes

  1. Bayley III scale at 24 months of age

    Bayley III scale is and individually administered instrument that assesses infant development across five domains, including cognitive, language and motor competencies. Parent reported questionnaires are incorporated to assess social-emotional and adaptative behaviors.

    Time frame: 24 months of corrected postnatal age

Secondary outcomes

  1. Cortical development

    Assessed by fetal brain magnetic resonance imaging.

    Time frame: 34 weeks of gestation

  2. Fetal brain volume

    Assessed by fetal brain magnetic resonance imaging.

    Time frame: 34 weeks of gestation

  3. Corpus callosum area

    Assessed by fetal neurosonography.

    Time frame: Enrolment, 32 and 36 weeks of gestation

  4. Neonatal weight

    Birth weight

    Time frame: Delivery

  5. Perinatal morbidity and mortality

    Development of one of the following conditions: pregnancy complications, perinatal mortality, metabolic acidosis and major neonatal morbidity.

    Time frame: Perinatal period: period ranging from 32 weeks of gestation (154 days) to the end of the first 4 weeks of neonatal life (28 days)

  6. Postnatal neurodevelopmental assessment

    Neurodevelopmental assessment using the Bayley III scale at 6 and 24 months of corrected postnatal age, as described in the primary outcome. A complementary neurodevelopmental assessment will be carried out in collaboration with the Speech Acquisition and Perception Groups of the University Pompeu Fabra Barcelona.

    Time frame: Between 4 and 24 months of corrected postnatal age

  7. Occurrence of adverse effects

    Record of side effects that may appear. Since intervention is usually well tolerated, we do not expect major side effects.

    Time frame: Through intervention (supplementation) completion, from enrolment to delivery

07

Study locations

6 of 6 sites recruiting
08

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Sep 2028, 68 months after the start.

Of 39 non-industry interventional studies with no phase under Fetal Growth Retardation, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 52. This study's planned 68 months is above that.

Counting every sponsor, half of 40 studies reached it within 35 months; a quarter within 18 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Sep 2026 → Sep 2028 and completion Dec 2026 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2021
First posted
Sep 9, 2021
StartActual
Jan 18, 2023
Primary completionEst.
Sep 2028was Sep 2026
CompletionEst.
Dec 2028was Dec 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (2 Spain)
  • Hospital Sant Joan de Déu · Esplugues de Llobregat, Spain
  • Hospital General del Hospitalet · L'Hospitalet de Llobregat, Spain
Show 2 removed
  • Hospital Sant Joan de Déu · Esplugues De Llobregat, Spain
  • Hospital General del Hospitalet · Hospitalet de Llobregat, Spain
Nov 9, 2026
Primary completion
Sep 2026→Sep 2028
Nov 9, 2026
Study completion
Dec 2026→Dec 2028
Nov 9, 2026
Sponsor
Collaborators removed: Fundacion Clinic per a la Recerca Biomédica
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 Spain)
    • Hospital Sant Joan de Déu · Esplugues de Llobregat, Spain
    • Hospital General del Hospitalet · L'Hospitalet de Llobregat, Spain
    Show 2 removed
    • Hospital Sant Joan de Déu · Esplugues De Llobregat, Spain
    • Hospital General del Hospitalet · Hospitalet de Llobregat, Spain
    Primary completion Sep 2026→Sep 2028
    Study completion Dec 2026→Dec 2028
    Sponsor Collaborators removed: Fundacion Clinic per a la Recerca Biomédica
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05038462
Lead sponsor
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Collaborators
Fundació Sant Joan de Déu
Responsible party
Elisenda Eixarch Roca (Coordinator of Fetal Neurology Unit, Institut d'Investigacions Biomèdiques August Pi i Sunyer) — Principal investigator
First posted
Sep 9, 2021
Start date
Jan 18, 2023
Primary completion
Sep 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

Elisenda Eixarch, MD; PhD
Contact
eixarch@clinic.cat
0034 932279333
Elena Monterde, MD
Contact
monterde@clinic.cat
0034 932279333

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lactoferrin

Start the discussion